Relation PK/PD des anticorps monoclonaux thérapeutiques utilisés en cancérologie

Monoclonal antibodies in oncology, used as targeted molecular therapy, coupled with cytotoxic or directed against immune checkpoints, present a complex pharmacokinetics essentially determined by their physicchemical characteristic. Further, an increasing number of studies show the existence of pharmacokineticpharmacodynamic relationship for many of them. Although they should be more frequent and should be conducted prospectively in the early clinical phases, these studies point out the need to integrate pharmacokinetic data of these biologics in the therapeutic management of cancer patients to optimize their use.